What Falling Estimates & Price Mean for Cempra (CEMP)


Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Cempra, Inc. (CEMP), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in CEMP.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 5 estimates moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, widening from a loss $1.68 a share a month ago to its current loss of $1.98.
Also, for the current quarter, Cempra has seen 2 downward estimate revisions versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 48 cents a share from a loss of 37 cents over the past 30 days.  
The stock also has seen some pretty dismal trading lately, as the share price has dropped 16.9% in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical - Drug industry, you may instead consider some better-ranked stocks including Aratana Therapeutics, Inc. (PETX), Lannett Company, Inc. (LCI) and Questcor Pharmaceuticals, Inc. (QCOR). All these stocks hold a Zacks Rank #1 (Strong Buy) and may be better selections at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

CEMPRA INC (CEMP): Free Stock Analysis Report


LANNETT COMP (LCI): Free Stock Analysis Report


Zacks Investment Research

View Comments (0)